ArticleFrontiers in medicine2026
A one-year exploratory randomized, controlled, multicentric pilot study evaluating the efficacy and tolerance of an anti-hair loss serum containing
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hair transplantation is a therapeutic option for androgenic alopecia (AGA) with visible results after 1 year. Post-transplant care may aid graft survival and growth, though few studies have assessed its efficacy. We evaluated the long-term tolerance and clinical efficacy of a hair serum containing two plant-derived active extracts ( Methods: In this 1-year exploratory randomized controlled trial, hair transplant patients received either study serum with neutral shampoo or shampoo alone. Tolerance and efficacy were evaluated by both investigators and patients at 0.5 month (M0.5) then M1, M3, M6, M9 and M12, depending on parameters, compared to baseline (before hair transplant). Results: Thirty men [median age: 40.0 (26.0-64.0) years], 15 per group, were included. Daily use of the serum on the recipient area post hair-transplant in men with AGA improved scalp tightness at M1 and discomfort perceived as painful at M0.5 ( Discussion: This first randomized controlled pilot trial suggested that this serum enhances global scalp aspect and hair state and appears to promote hair growth after transplantation, thus acting as a safe, dermocosmetic adjuvant for optimal long-term post-procedure hair care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.